{"id":266741103,"generated_unique_award_id":"ASST_NON_F32HL176217_075","fain":"F32HL176217","uri":"F32HL176217-3471552337","category":"grant","type":"04","type_description":"PROJECT GRANT (B)","description":"EXAMINING DIETARY AND METABOLOMICS PATTERNS ON CARDIOMETABOLIC OUTCOME VARIABILITY IN RESPONSE TO CALORIE RESTRICTION - PROJECT SUMMARY CARDIOVASCULAR DISEASE (CVD) IS THE LEADING CAUSE OF MORTALITY AND MORBIDITY WORLDWIDE, WITH AGE BEING THE STRONGEST INDEPENDENT NON-MODIFIABLE RISK FACTOR. CALORIE RESTRICTION (CR), THE REDUCTION OF TOTAL FOOD INTAKE LESS THAN THE RECOMMENDED ENERGY REQUIREMENT, IS THE MOST EFFICACIOUS DIETARY INTERVENTION TO PROLONG LIFESPAN AND DECREASE CVD RISK. IN THE LARGEST CLINICAL TRIAL OF CR (CALERIETM 2), HEALTHY ADULTS WERE RANDOMIZED TO EITHER 2 YEARS OF CR (N=143) OR AN AB LIBITUM (AL) (N=75) CONTROL GROUP. THE CR GROUP ACHIEVED ~12% CR OVER 2 YEARS AND HAD IMPROVEMENTS IN CARDIOMETABOLIC HEALTH OUTCOMES SUCH AS THE CHANGE IN BLOOD PRESSURE, BLOOD LIPIDS, AND FASTING GLUCOSE LEVELS FROM BASELINE TO 2 YEARS. HOWEVER, PRELIMINARY ANALYSES SHOW LARGE INTERINDIVIDUAL VARIABILITY IN THE MAGNITUDE AND DIRECTION OF CARDIOMETABOLIC HEALTH OUTCOMES IN RESPONSE TO THE CR IMPACTING INTERVENTION EFFICACY. THERE WAS NO SPECIFIC DIET PRESCRIBED TO CR PARTICIPANTS IN CALERIETM 2, BUT RATHER PARTICIPANTS WERE EDUCATED ON HOW TO CHOOSE THEIR OWN FOODS TO ACHIEVE SATIETY, MITIGATE HUNGER, AND TO REACH THE DIETARY RECOMMENDED INTAKES. PRELIMINARY ANALYSIS INDEED SHOWS THAT THERE WAS INTERINDIVIDUAL VARIABILITY IN THE CHANGE IN DIET QUALITY (MEASURED BY THE HEALTHY EATING INDEX) FROM BASELINE TO 2 YEARS OF CR. CONSUMING NUTRIENT-RICH FOODS SUCH AS FRUITS, VEGETABLES, WHOLE GRAINS, AND FISH IS BENEFICIAL FOR CARDIOMETABOLIC HEALTH AND ARE CONSUMED THROUGHOUT THE LONGEST-LIVED POPULATIONS. THUS, WE HYPOTHESIZE THAT DIET QUALITY CONTRIBUTES TO THE CARDIOMETABOLIC HEALTH OUTCOME VARIABILITY OBSERVED WITH THE 2-YEAR CR INTERVENTION. WE WILL COMPUTE NOVEL DIETARY SCORES (E.G., HEALTHY EATING INDEX AND DIETARY INFLAMMATORY INDEX) FROM 6-DAY FOOD RECORDS TAKEN AT BASELINE AND MONTHS 12 AND 24 (FOOD RECORDS WERE ALSO TAKEN AT MONTHS 6 AND 18 FOR THE CR GROUP) TO MEASURE DIET QUALITY. THE PRIMARY OUTCOME IS CHANGE IN BLOOD PRESSURE, AND SECONDARY OUTCOMES ARE CHANGES IN BLOOD LIPIDS, GLUCOSE, INSULIN, VO2MAX, 10-Y CVD RISK SCORE, AND BIOMARKERS OF INFLAMMATION AND OXIDATIVE STRESS. THEN, WE WILL DETERMINE WHETHER DIET QUALITY SCORES ARE ASSOCIATED WITH THE CHANGE IN THE PRIMARY AND SECONDARY CARDIOMETABOLIC HEALTH OUTCOMES ACROSS EACH TIMEPOINT. WE WILL ALSO MERGE UNTARGETED METABOLOMICS DATA FROM CALERIETM 2 PARTICIPANTS AT BASELINE AND MONTHS 12 AND 24 WITH THE DIET QUALITY SCORES TO IDENTIFY UNIQUE METABOLOMIC CLUSTER SIGNATURES FOR EACH DIET SCORE. APPLYING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING APPROACHES, WE AIM TO BUILD PREDICTION MODELS THAT WILL DETERMINE THE MOST OPTIMAL DIETARY PATTERN IN THE CONTEXT OF CR TO IMPROVE CARDIOMETABOLIC HEALTH AT THE INDIVIDUAL LEVEL. THIS PROJECT WILL CONTRIBUTE TO THE EMERGING FIELD OF PRECISION NUTRITION RESEARCH BY IDENTIFYING FACTORS CONTRIBUTING TO OUTCOME VARIABILITY TO DIETARY INTERVENTIONS. FURTHERMORE, I WILL LEARN INVALUABLE SKILLS TO ADVANCE MY GOAL OF BECOMING AN INDEPENDENT CLINICAL RESEARCHER IN PRECISION NUTRITION FOR HEALTHY AGING.","subaward_count":0,"total_subaward_amount":null,"total_subsidy_cost":0.0,"total_loan_value":0.0,"total_obligation":158348.0,"date_signed":"2024-08-09","base_and_all_options":null,"base_exercised_options":null,"non_federal_funding":0.0,"total_funding":158348.0,"total_account_outlay":79156.73,"total_account_obligation":158348.0,"account_outlays_by_defc":[{"code":"Q","amount":79156.73}],"account_obligations_by_defc":[{"code":"Q","amount":158348.0}],"record_type":2,"cfda_info":[{"applicant_eligibility":"Local (includes State-designated Indian Tribes; excludes institutions of higher education and hospitals), Public nonprofit institution/organization (includes institutions of higher education and hospitals), Individual/Family, Small business (less than 500 employees), Private nonprofit institution/organization (includes institutions of higher education and hospitals)\n. Any nonprofit organization engaged in biomedical research and institutions or companies organized for profit may apply for almost any kind of grant. Only domestic, non-profit, private or public institutions may apply for NRSA Institutional Research Training Grants. An individual may apply for an NRSA or, in some cases, for a research grant if adequate facilities to perform the research are available. SBIR grants can be awarded only to United States small business concerns (entities that are independently owned and operated for profit or owned by another small business that itself is independently owned and operated for profit, or owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these and have no more than 500 employees including affiliates). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions except under rare and unique circumstances where foreign components are thoroughly justified and necessary to the overall completion of the project. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. Normally, SBIR projects must be performed at least 67% by the applicant small business in Phase I and at least 50% of the Project in Phase II. STTR grants can be awarded only to United States small business concerns (entities that are independently owned and operated for profit and have no more than 500 employees) that formally collaborate with a university or other non-profit research institution in cooperative research and development. The principal investigator of an STTR award may be employed with either the small business concern or collaborating non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant small business concern and is willing to devote at least 10% effort (1.2 calendar months) to the project. At least 40% of the project is to be performed by the small business concern and at least 30% by the non-profit research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions except under rare and unique circumstances where foreign components are thoroughly justified and necessary to the overall completion of the project.","beneficiary_eligibility":"Any nonprofit or for-profit organization, company or institution engaged in biomedical research.  Only domestic for-profit small business firms may apply for SBIR and STTR programs.","cfda_federal_agency":"NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF","cfda_number":"93.837","cfda_objectives":"The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. To foster heart and vascular research in the basic, translational, clinical and population sciences, and to foster training to build talented young investigators in these areas, funded through competitive research training grants. Small Business Innovation Research (SBIR) program: To stimulate technological innovation; use small business to meet Federal research and development needs; foster and encourage participation in innovation and entrepreneurship by socially and economically disadvantaged persons; and increase private-sector commercialization of innovations derived from Federal research and development funding. Small Business Technology Transfer (STTR) program: To stimulate technological innovation; foster technology transfer through cooperative R&D between small businesses and research institutions, and increase private sector commercialization of innovations derived from federal R&D.","cfda_obligations":"(Grant) FY 24$1,525,396,994.00; FY 25$1,564,175,161.00; FY 26 est $0.00; - (Cooperative Agreement) FY 24$129,058,340.00; FY 25$125,864,272.00; FY 26 est $0.00; - ","cfda_popular_name":"","cfda_title":"Cardiovascular Diseases Research","cfda_website":"https://www.nhlbi.nih.gov/about/scientific-divisions/division-cardiovascular-sciences","federal_action_obligation_amount":158348.0,"non_federal_funding_amount":0.0,"sam_website":"https://sam.gov/fal/cde130aceabc40edbebf1cb48f3f83d7/view","total_funding_amount":158348.0}],"transaction_obligated_amount":158348.0,"funding_agency":{"id":830,"has_agency_page":true,"toptier_agency":{"name":"Department of Health and Human Services","code":"075","abbreviation":"HHS","slug":"department-of-health-and-human-services"},"subtier_agency":{"name":"National Institutes of Health","code":"7529","abbreviation":"NIH"},"office_agency_name":"NIH National Heart, Lung, and Blood Institute"},"awarding_agency":{"id":830,"has_agency_page":true,"toptier_agency":{"name":"Department of Health and Human Services","code":"075","abbreviation":"HHS","slug":"department-of-health-and-human-services"},"subtier_agency":{"name":"National Institutes of Health","code":"7529","abbreviation":"NIH"},"office_agency_name":"NIH National Heart, Lung, and Blood Institute"},"period_of_performance":{"start_date":"2024-08-12","end_date":"2026-08-11","last_modified_date":"2025-08-20"},"recipient":{"recipient_hash":"ee43b4c1-f169-4410-1238-fdd624d3805b-C","recipient_name":"PENNINGTON BIOMEDICAL RESEARCH CENTER","recipient_uei":"MWYVQTQ32ME5","recipient_unique_id":null,"parent_recipient_hash":"ee43b4c1-f169-4410-1238-fdd624d3805b-P","parent_recipient_name":"PENNINGTON BIOMEDICAL RESEARCH CENTER","parent_recipient_uei":"MWYVQTQ32ME5","parent_recipient_unique_id":null,"business_categories":["Higher Education","Higher Education (Public)"],"location":{"location_country_code":"USA","country_name":"UNITED STATES","state_code":"LA","state_name":"LOUISIANA","city_name":"BATON ROUGE","county_code":"033","county_name":"EAST BATON ROUGE","address_line1":"6400 PERKINS RD","address_line2":null,"address_line3":null,"congressional_code":"06","zip4":"4124","zip5":"70808","foreign_postal_code":null,"foreign_province":null}},"executive_details":{"officers":[{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null}]},"place_of_performance":{"location_country_code":"USA","country_name":"UNITED STATES","county_code":"033","county_name":"EAST BATON ROUGE","city_name":"BATON ROUGE","state_code":"LA","state_name":"LOUISIANA","congressional_code":"06","zip4":"4124","zip5":"70808","address_line1":null,"address_line2":null,"address_line3":null,"foreign_province":null,"foreign_postal_code":null},"total_outlay":79156.73,"funding_opportunity":{"number":"PA-23-262","goals":"TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS.  SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D."}}